News

Publication of a clinical phase 1 study of SCO-240: SSTR5 antagonist is a novel strategy to treat growth hormone-related disorders

SCOHIA PHARMA and Huadong Announce Global Expansion of the Strategic Collaboration for SCO-094

Issuance of Key Patent Covering Novel Nrf2 Activator

Kuria Therapeutics and SCOHIA PHARMA Announce Strategic Licensing Agreement for Ophthalmic and Dermal Rights to SCO-116, A Novel Nrf2 Activator

Awarded the 3rd prize of the Boehringer Ingelheim Innovation Prize, 2021

IP6K inhibitor（SCO-006）information has been updated

The clinical results of SCO-267 was presented at the Virtual 81st Scientific Sessions – American Diabetes Association: First report on the clinical data of a GPR40 full agonist in the phase 1 trial

Huadong and SCOHIA PHARMA Announce Strategic Collaboration to Develop, Manufacture and Commercialize SCO-094 in Asia Pacific

SCOHIA initiates a phase 1 study on an SSTR5 antagonist (SCO-240)

SCOHIA initiates a phase 1 study on a dual GLP-1 and GIP receptor agonist (SCO-094)